...ovarian cancer in the first dose cohort of a Phase Ib trial showing that subcutaneous DPX-Survivac...
...Preliminary data from the first three evaluable patients in the second dose cohort showed that DPX-Survivac...
...TILs). Secondary endpoints include ORR, duration of response, time to progression and overall survival (OS). DPX-Survivac...

...Immunovaccine and Merck partnered to evaluate Immunovaccine’s DPX-Survivac in combination with Merck’s cancer drug Keytruda pembrolizumab...
...Margaret Cancer Center will conduct. Keytruda is a humanized IgG4 mAb against PD-1 , and DPX-Survivac...
...Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Alicia Parker DPX-Survivac Keytruda pembrolizumab Immunovaccine...

...Phase I/II trial in 54 evaluable patients with stage IIc-IV ovarian cancer showed that subcutaneous DPX-Survivac...
...patients who generated T cell responses, 79% maintained “durable immune responses” over time with repeated DPX-Survivac...
...increased levels of inhibitory checkpoint molecules after treatment. Immunovaccine said the optimal dosing schedule of DPX-Survivac...

...The companies partnered non-exclusively to evaluate Immunovaccine’s DPX-Survivac in combination with epacadostat from Incyte plus low-dose...
...the trial, which Immunovaccine will conduct. Epacadostat is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, and DPX-Survivac...

...DPX-Survivac plus oral cyclophosphamide in up to 24 patients. Subjects will receive 2 doses of DPX-Survivac...
...followed by booster doses every 2 months. Immunovaccine Inc . (TSX:IMV), Halifax, Nova Scotia Product: DPX-Survivac...

...undergone bone marrow transplantation. Immunovaccine Inc. (TSX-V:IMV) gained C$0.18 (26%) to C$0.88 last week after DPX-Survivac...

...open-label, dose-ranging Phase I/Ib portion of a North American Phase I/II trial showed that subcutaneous DPX-Survivac...
...patient achieved a reduction in CA-125 levels and a significant increase in vaccine-induced immune responses. DPX-Survivac...
...Phase I/II trial of DPX-Survivac to treat glioblastoma. Immunovaccine Inc. (TSX-V:IMV), Halifax, Nova Scotia Product: DPX-Survivac...

...portion of a North American Phase I/II trial showed that all 12 patients receiving subcutaneous DPX-Survivac...
...immunospot (ELISPOT) assay, tetramer analysis and multiparametric intracellular cell staining). Additionally, all 10 patients receiving DPX-Survivac...
...of the trial is evaluating 0.5 mL DPX-Survivac as monotherapy or 0.1 and 0.5 mL DPX-Survivac...

...Phase I portion of a North American Phase I/II trial showed that 0.5 mL subcutaneous DPX-Survivac...
...and generally showed higher antigen-specific immunity compared to 0.1 mL DPX-Survivac plus cyclophosphamide. Additionally, high-dose DPX-Survivac...
...surgery and chemotherapy to receive 0.5 mL DPX-Survivac as monotherapy or 0.1 and 0.5 mL DPX-Survivac...

...of the Phase I portion of a Phase I/II trial showed that 0.5 mL subcutaneous DPX-Survivac...
...enrolling 15 patients to receive 0.5 mL DPX-Survivac as monotherapy or 0.1 and 0.5 mL DPX-Survivac...
...low-dose oral cyclophosphamide. The double-blind, placebo-controlled Phase II portion will evaluate the optimal dose of DPX-Survivac...